ClinicalTrials.gg
TerminatedNCT03211988Updated Mar 2, 2026Results posted

Entinostat Neuroendocrine (NE) Tumor

A Phase 2 interventional study of Entinostat in Neuroendocrine Tumors, sponsored by Antonio Fojo. Terminated at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Antonio Fojo · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Lack of funding and drug supply

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 219 studies in Neuroendocrine Tumors with a site in United States — 45 open to participants now, 77 under way, 10 of them phase 3. Neuroendocrine Tumors · United States.

Enrollment
174th of 190
5 · median 35
Started
2017
with 21 others
Phase 2
83 of 219
12 open now
Registered
113th of 219
by date

Among the 219 studies in Neuroendocrine Tumors with a site in United States, this one is the 174th largest by enrollment of the 190 interventional ones that give a count, is one of 22 that started in 2017, is one of 83 in phase 2, and was the 113th registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

45 of the 219 studies in Neuroendocrine Tumors with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Neuroendocrine Tumors with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, single arm, multi-center Phase II trial of entinostat given as a 5 mg oral dose every week (days 1, 8, 15, and 22 of a 4-week cycle) in patients with relapsed or refractory abdominal neuroendocrine (NE) tumors. Patients will continue on treatment until disease progression or intolerable toxicity occurs.

Read the detailed description

Neuroendocrine tumors (NETs) are derived from NE cells that reside widely in the endocrine system and other organs and comprise a heterogeneous group of neoplasms. Because NETs can arise in a broad spectrum of locations they are associated with a broad range of symptoms that may be caused by mass effects and/or by the production of hormones or biogenic amines.

Most recently, entinostat has been shown to down-regulate the number and function of two key immunosuppressive cells, myeloid derived suppressor cells (MDSCs) and regulatory T-cells (Tregs), in the tumor microenvironment thereby enhancing the activity of immune checkpoint inhibition. To date, entinostat has been investigated alone or in combination in >900 patients with cancer in clinical studies, including >600 patients with solid tumors. Entinostat as a single agent has been studied in metastatic melanoma and in combination has been studied in metastatic non-small cell lung cancer (NSCLC), breast cancer, renal cell cancer, and colon cancer.

03

Conditions studied

  • Neuroendocrine Tumors

Keywords

  • abdominal
  • neuroendocrine tumor
  • columbia
  • relapsed
  • refractory
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed stage intravenous (IV) unresectable , or unresectable refractory abdominal neuroendocrine tumor from the last available which may be the initial diagnostic biopsy.

    Relapsed disease is defined as progressive disease following systematic therapy with lanreotide or equivalent and either Sunitinib or everolimus or both. Refractory disease is defined as disease not responding to or having progressed within 1 month of the last dose of most recent systemic therapy to include lanreotide or an analog and either sunitinib or everolimus. (Note, small cell carcinoma and large cell undifferentiated neuroendocrine tumors will be excluded from this trial).

  2. Eligibility for stage 2 of the study, if the extension stage is opened, will be determined by ribonucleic acid-sequencing (RNA-seq) analysis and master regulator profile of a single fresh needle biopsy specimen obtained during study screening.
  3. Documented disease that is radiographically measurable.
  4. Last dose of prior therapy must be > 21 days before the first dose of study drug administration. There is no upper limit to number of prior therapies. However, the patient must have recovered from acute toxicities from the most recent therapy to grade 1 or less.
  5. (ECOG) performance status of 0 or 1 (must be done within 7 days prior to study drug administration).
  6. Age 18 years or older
  7. Total ≤ 1.5 x (ULN) and (AST) and alanine aminotransferase (ALT) \< 2.5 x ULN (results within 7 days before study drug administration), ≤5×ULN for patients with liver .
  8. Serum creatinine ≤ 1.5 x ULN (results within 7 days before study drug administration)
  9. of ≥ 1500/μL (without growth factor support), counts ≥100,000/μL (without transfusion support); and ≥9 g/dL results within 7 days before study drug administration.
  10. Patients or their legal representative must be able to read, understand, and sign a written
  11. (INR) or Prothrombin Time (PT) ≤1.5×ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants and activated partial Thromboplastin Time (aPTT) ≤1.5×ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  12. If a female of , has a negative serum blood pregnancy test during screening and a negative urine pregnancy test within 3 days prior to receiving the first dose of study drug. If the screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test is not required. Note: Women of childbearing potential (WoCP) are any women between menarche and menopause who have not been permanently or surgically sterilized and are capable of procreation. Permanent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy but excludes bilateral tubal occlusion. WoCP include non-women who have experienced menopause onset \< 12 months prior to enrollment.
  13. If a female of childbearing potential, willing to use 2 methods of or willing to abstain from heterosexual activity for the course of the study through 120 days after the last dose of study drug.
  14. If male, agrees to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

Patients fulfilling any of the following criteria will not be admitted into the study:

  1. Patients with another active cancer (excluding basal cell carcinoma or cervical intraepithelial neoplasia (Cervical Intraepithelial Neoplasia (CIN) / cervical carcinoma in situ) or melanoma in situ)). Prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years.
  2. Pregnant or lactating women. Women of (WOCBP) must have a negative serum pregnancy test documented within 3 days prior to start of study drug.
  3. Patients with uncontrolled intercurrent illness, active or uncontrolled infections, or a fever >38.5°C that has not been evaluated for infection up to the day of initial dosing. Patients with documented history of tumor fever are accepted provided acute or chronic infection has been excluded as possible cause of the fever.
  4. Patients who have been treated with any drug within 28 days prior to the first dose of study medication, or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy.
  5. Prior treatment with histone deacetylase (HDAC) inhibitors (e.g. valproic acid, Zolinza® (SAHA), romidepsin (Istodax®).
  6. History of pericarditis or pericardial effusion that had required medical or surgical intervention in the last 6 months, or myocardial infarction or arterial thromboembolic events within 6 months, or experiencing severe or unstable angina, or (NYHA) Class III or IV disease, or a (QTc) interval >0.47 seconds
  7. Known (HIV) or a history of active or C as evidenced by laboratory abnormalities in addition to positive serology. Testing is not required for patients not suspected of having these conditions
  8. Any condition (e.g., known or suspected poor compliance, psychological instability, geographical location, etc) that, in the judgment of the investigator, may affect the patient's ability to sign the and comply with study procedures
  9. Any condition that will put the patient at undue risk or discomfort as a result of adherence to study procedures
  10. Presence or history of .
  11. Uncontrolled hypertension or diabetes mellitus
  12. Any to oral agents or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the investigator, would preclude adequate absorption.
  13. Allergy to benzamide or inactive components of entinostat.
  14. Patients may not be taking any for any reason while on study and all corticosteroids must be stopped two weeks prior to initiation of study drug.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Other
    Entinostat

    Eligible patients will be enrolled according to Simon's two-stage design. The dose of Entinostat is 5 mg (one tablet) orally, once every week in a 28 day cycle.

    Drug: Entinostat

Interventions

  • Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.

    Also known as: SNDX-275, MS-275

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective response defined as complete response (CR) (Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.) and partial response (PR) (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) and will be determined from each participant's best confirmed response during protocol therapy. Response as evaluated per RECIST 1.1 criteria.

    Time frame: Up to 44 months

Secondary outcomes

  1. Duration of Progression-Free Survival (PFS)

    Time from study enrollment until disease progression or death.

    Time frame: Up to 45 months

  2. Duration of Overall Survival (OS)

    The length of time from either the date of diagnosis or start of treatment that years participants diagnosed with the disease are still alive.

    Time frame: Up to 45 months

  3. Duration of Response for Participants Who Achieve Complete Response (CR) or Partial Response (PR)

    Time from documentation of tumor response to disease progression in participants who achieve CR or PR.

    Time frame: Up to 4 years

07

Results

Posted Mar 2, 2026

Participant flow

Participant flow — Overall Study
MilestoneEntinostat
Started5
Completed4
Not completed1
Withdrew: Death1

Outcome measures

PrimaryObjective Response Rate (ORR)

Objective response defined as complete response (CR) (Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.) and partial response (PR) (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) and will be determined from each participant's best confirmed response during protocol therapy. Response as evaluated per RECIST 1.1 criteria.

Time frame:
Up to 44 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsEntinostat
Objective Response Rate (ORR)0
SecondaryDuration of Progression-Free Survival (PFS)

Time from study enrollment until disease progression or death.

Time frame:
Up to 45 months
Reported as:
Median · days
Duration of Progression-Free Survival (PFS)
daysEntinostat
Duration of Progression-Free Survival (PFS)381 (232 to 754)
SecondaryDuration of Overall Survival (OS)

The length of time from either the date of diagnosis or start of treatment that years participants diagnosed with the disease are still alive.

Time frame:
Up to 45 months
Reported as:
Median · days
Duration of Overall Survival (OS)
daysEntinostat
Duration of Overall Survival (OS)1422 (1163 to 1611)
SecondaryDuration of Response for Participants Who Achieve Complete Response (CR) or Partial Response (PR)

Time from documentation of tumor response to disease progression in participants who achieve CR or PR.

Time frame:
Up to 4 years

No measurements were reported for this outcome.

Adverse events

Collected over Through study completion, an average of 3 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entinostat1/5 (20%)1/5 (20%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventEntinostat
Cardiac arrestCardiac disorders1/5
Most frequent other events
Showing 10 of 25
Most frequent other events
EventEntinostat
NauseaGastrointestinal disorders4/5
Neutrophil count decreasedInvestigations4/5
VomitingGastrointestinal disorders3/5
FatigueGeneral disorders3/5
Flu-like symptomsGeneral disorders3/5
AnorexiaMetabolism and nutrition disorders2/5
AnemiaBlood and lymphatic system disorders2/5
Abdominal PainGastrointestinal disorders1/5
HypophosphatemiaMetabolism and nutrition disorders1/5
HyperkalemiaMetabolism and nutrition disorders1/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entinostat
Median75 (59 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)Entinostat
Female1
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Entinostat
Hispanic or Latino0
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Entinostat
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White4
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
09

References and documents

Publications

  • Jamison JK, Zhou M, Gelmann EP, Luk L, Bates SE, Califano A, Fojo T. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. Oncologist. 2024 Sep 6;29(9):817-e1213. doi: 10.1093/oncolo/oyae118. PubMed 38886159 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Aug 2021, 44 months.

Results were first posted in Mar 2026, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2017
First posted
Jul 11, 2017
StartActual
Dec 13, 2017
Primary completionActual
Aug 24, 2021
CompletionActual
Oct 6, 2021
Results first posted
Mar 2, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03211988
Lead sponsor
Antonio Fojo
Responsible party
Antonio Fojo (Professor of Medicine, Columbia University) — Sponsor-investigator
First posted
Jul 11, 2017
Start date
Dec 13, 2017
Primary completion
Aug 24, 2021
Completion
Oct 6, 2021
Results posted
Mar 2, 2026
Last update
Mar 2, 2026

Study contacts

Antonio Fojo, MD, PhD
principal investigator · Columbia University/Herbert Irving Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entinostat

Start the discussion